Accelerating Medical Treatments for Serious Mental Illness
1. Purpose
To accelerate innovative research models and drug approvals for psychedelic drugs to enhance access and address serious mental illness in the U.S.
2. Key Actions And Directives
- Prioritize FDA Review: The FDA is to prioritize the review of psychedelic drugs with Breakthrough Therapy designation and facilitate patient access under the Right to Try Act.
- Allocate Funding for State Programs: The Secretary of Health and Human Services will allocate at least $50 million to support state programs developing psychedelic drug initiatives.
- Enhance Collaboration among Federal Entities: Encourage collaboration between the Department of Health and Human Services, FDA, Department of Veterans Affairs, and private sector for data sharing and clinical trial participation.
- Review Schedule I Substances: The Attorney General is directed to review any product containing a Schedule I substance that has completed Phase 3 trials for serious mental disorders for rescheduling.
3. Important Points
- Mental Illness Statistics: Over 14 million American adults suffer from serious mental illnesses, highlighting the urgency for effective interventions.
- Rise in Suicide Rates: Suicide rates in the U.S. significantly increased by 37% from 2000 to 2018.
- Veteran Suicide Crisis: Veterans face a suicide rate over twice that of non-veteran adults, with 6,000 veteran suicides annually.
- Limitations of the Executive Order: The Executive Order does not create enforceable rights or benefits for any parties against the U.S. or its entities.
- Focus on Innovative Treatments: The focus on psychedelic drugs is part of a broader strategy to explore innovative treatments for mental health.
Disclaimer: ExecBrief's are AI generated, Please verify with the original source to confirm
Click here to provide feedback to help us improve your experience!
Comments